Search Results - "Gaya, D"

Outpatient management of patients with low-risk upper-gastrointestinal haemorrhage: multicentre validation and prospective evaluation by Stanley, AJ, Dr, Ashley, D, BMBS, Dalton, HR, DPhil, Mowat, C, MD, Gaya, DR, MBChB, Thompson, E, MBChB, Warshow, U, MBBS, Groome, M, MBChB, Cahill, A, MB, Benson, G, BSc, Blatchford, O, MD, Murray, W, MD

“…Summary Background Upper-gastrointestinal haemorrhage is a frequent reason for hospital admission. Although most risk scoring systems for this disorder…”
Get full text

Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis by Kennedy, N. A., Warner, B., Johnston, E. L., Flanders, L., Hendy, P., Ding, N. S., Harris, R., Fadra, A. S., Basquill, C., Lamb, C. A., Cameron, F. L., Murray, C. D., Parkes, M., Gooding, I., Ahmad, T., Gaya, D. R., Mann, S., Lindsay, J. O., Gordon, J., Satsangi, J., Hart, A., McCartney, S., Irving, P., Lees, C. W., Ahmad, Tariq, Basavaraju, Umesh, Christodoulou, Christos, Cummings, Fraser, Grieveson, Kay, Johnston, Matthew, Lal, Simon, Lithgo, Karen, Lockett, Melanie, Maggs, Daniel, Mansfield, John, Mason, Joy, Nowell, Emma, Parkes, Miles, Russell, Richard, Singh, Abhey, Stansfield, Catherine, Thomson, John, Wilson, David C.

“…Summary Background Infliximab and adalimumab have established roles in inflammatory bowel disease (IBD) therapy. UK regulators mandate reassessment after 12…”
Get full text

Multicentre comparison of the Glasgow Blatchford and Rockall scores in the prediction of clinical end‐points after upper gastrointestinal haemorrhage by Stanley, A. J., Dalton, H. R., Blatchford, O., Ashley, D., Mowat, C., Cahill, A., Gaya, D. R., Thompson, E., Warshow, U., Hare, N., Groome, M., Benson, G., Murray, W.

“…Aliment Pharmacol Ther 2011; 34: 470–475 Summary Background  The Glasgow Blatchford Score (GBS) is increasingly being used to predict intervention and outcome…”
Get full text

A prospective single‐centre evaluation of the intra‐individual variability of faecal calprotectin in quiescent Crohn's disease by Naismith, G. D., Smith, L. A., Barry, S. J. E., Munro, J. I., Laird, S., Rankin, K., Morris, A. J., Winter, J. W., Gaya, D. R.

“…Summary Background As a non‐invasive marker of gastrointestinal inflammation, faecal calprotectin (FC) is being increasingly used to guide the management of…”
Get full text

Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients by Kennedy, N. A., Kalla, R., Warner, B., Gambles, C. J., Musy, R., Reynolds, S., Dattani, R., Nayee, H., Felwick, R., Harris, R., Marriott, S., Senanayake, S. M., Lamb, C. A., Al‐Hilou, H., Gaya, D. R., Irving, P. M., Mansfield, J., Parkes, M., Ahmad, T., Cummings, J. R. F., Arnott, I. D., Satsangi, J., Lobo, A. J., Smith, M., Lindsay, J. O., Lees, C. W.

“…Summary Background Thiopurines (azathioprine and mercaptopurine) remain integral to most medical strategies for maintaining remission in Crohn's disease (CD)…”
Get full text

Hepatic granulomas: a 10 year single centre experience by Gaya, D R, Thorburn, D, Oien, K A, Morris, A J, Stanley, A J

“…Background: Epithelioid granulomas have been reported in 2–15% of unselected liver biopsies, with numerous underlying aetiologies described. However, all UK…”
Get full text

Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort by Plevris, N, Chuah, C S, Allen, R M, Arnott, I D, Brennan, P N, Chaudhary, S, Churchhouse, A M D, Din, S, Donoghue, E, Gaya, D R, Groome, M, Jafferbhoy, H M, Jenkinson, P W, Lam, W L, Lyons, M, Macdonald, J C, MacMaster, M, Mowat, C, Naismith, G D, Potts, L F, Saffouri, E, Seenan, J P, Sengupta, A, Shasi, P, Sutherland, D I, Todd, J A, Veryan, J, Watson, A J M, Watts, D A, Jones, G R, Lees, C W

“…Vedolizumab is an anti-a4b7 monoclonal antibody that is licensed for the treatment of moderate to severe Crohn's disease and ulcerative colitis. The aims of…”
Get full text

Long-term follow-up of endoscopic Histoacryl glue injection for the management of gastric variceal bleeding by RAJORIYA, N, FORREST, E. H, GRAY, J, STUART, R. C, CARTER, R. C, MCKAY, C. J, GAYA, D. R, MORRIS, A. J, STANLEY, A. J

“…Variceal bleeding is an acute medical emergency with high mortality. Although less common than oesophageal variceal haemorrhage, gastric variceal bleeding is…”
Get full text

PP057-MON FINAL ADULT HEIGHT & BODY PROPORTIONS IN YOUNG ADULTS WITH CHILDHOOD ONSET AND ADULT ONSET CROHN'S DISEASE (CD) by Mason, A, Iljuhhina, J, Gaya, D, Ahmed, F, Gerasimidis, K

Get full text

Are we exposing patients with a mildly elevated faecal calprotectin to unnecessary investigations? by Seenan, J P, Thomson, F, Rankin, K, Smith, K, Gaya, D R

“…ObjectiveFaecal calprotectin (FC) is a non-invasive marker used to differentiate irritable bowel syndrome from inflammatory bowel disease (IBD). However, false…”
Get full text

Faecal calprotectin in the assessment of Crohn's disease activity by Gaya, D.R., Lyon, T.D.B., Duncan, A., Neilly, J.B., Han, S., Howell, J., Liddell, C., Stanley, A.J., Morris, A.J., Mackenzie, J.F.

“…Background: Clinical and laboratory assessment of activity in Crohn's disease (CD) correlate poorly with endoscopic findings. Calprotectin is a calcium-binding…”
Get full text

Anti-TNF-α therapy for orofacial granulomatosis: proceed with caution by Gaya, D R, Aitken, S, Fennell, J, Satsangi, J, Shand, A G

Get full text

Faecal calprotectin: a bright future for assessing disease activity in Crohn's disease by Gaya, D.R., Mackenzie, J.F.

Get full text

Brown spots in the bowel by Gaya, D R, Stanley, A J, Foulis, A K

Get full text

A tale of two sisters by Gaya, D R, McLay, A L C, Oien, K A, Spooner, R J, Reilly, T G

“…Hereditary haemochromatosis is the most common inherited disorder in white populations, whereas non-alcoholic steatohepatitis (NASH) is becoming the most…”
Get full text

A woman with dysphagia and Raynaud's phenomenon by Gaya, D R, Mactier, R

Get full text

Liver biopsy--on the ward or at radiology? by Gaya, D R

Get more information

P804 Development and Validation of the Glasgow Exclusive Enteral Nutrition Index of Compliance (GENIE) by Jatkowska, A, White, B, Nichols, B, Svolos, V, Gkikas, K, Hansen, R, Russell, R K, Gaya, D, Brownson, E, Seenan, J P, Milling, S, MacDonald, J, Gerasimidis, K

“…Abstract Background Treatment adherence is key to the efficacy of exclusive enteral nutrition (100% EN) in active Crohn’s disease (CD), but there are currently…”
Get full text

P518 Dietary and non-dietary predictors of treatment response to adalimumab in anti-TNFα-naïve adults with Crohn’s disease by Jatkowska, A, White, B, Campbell, I, Brownson, E, Short, B, Clowe, J, Seenan, J P, Gaya, D R, Din, S, Ho, G T, Robertson, E, Mowat, C, Milling, S, MacDonald, J, Gerasimidis, K

“…Abstract Background Biologics, such as anti-TNFα agents, are commonly used in the management of Crohn’s disease (CD). A significant proportion of patients do…”
Get full text

P681 Preliminary data from the Biologic and Partial Enteral Nutrition in Crohn’s Disease Study (BIOPIC) by White, B, Jatkowska, A, Campbell, I, Brownson, E, Short, B, Clowe, J, Seenan, J P, Gaya, D, Din, S, Ho, G T, Robertson, E, Mowat, C, Milling, S, Macdonald, J, Gerasimidis, K

“…Abstract Background Biologics such as adalimumab (ADA) are used to induce clinical remission (CR) in individuals with active Crohn’s disease (CD) but around…”
Get full text